A search for cyclophilin‐A gene variants in cyclosporine A‐treated renal transplanted patients

Abstract: Background:  The cyclophilin A (CypA) ‐ cyclosporine (CsA) complex promotes immune response. The variation at the CypA gene could explain CsA‐pharmacokinetics and clinical outcomes among CsA‐treated patients.

[1]  K. Budde,et al.  Pharmacokinetic principles of immunosuppressive drugs. , 2008, Annals of transplantation.

[2]  V. Álvarez,et al.  A search for cyclophilin‐A gene (PPIA) variation and its contribution to the risk of atherosclerosis and myocardial infarction , 2008, International journal of immunogenetics.

[3]  Santiago Rodríguez,et al.  Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX' , 2007, BMC Bioinformatics.

[4]  J. Goedert,et al.  Regulatory Polymorphisms in the Cyclophilin A Gene, PPIA, Accelerate Progression to AIDS , 2007, PLoS pathogens.

[5]  K. Salmela,et al.  Early Cyclosporine C0 and C2 Monitoring in De Novo Kidney Transplant Patients: A Prospective Randomized Single-Center Pilot Study , 2006, Transplantation.

[6]  S. Lamas.  Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. , 2005, Kidney international.

[7]  Ping Wang,et al.  The cyclophilins , 2005, Genome Biology.

[8]  J. Luban,et al.  Cyclophilin A-Deficient Mice Are Resistant to Immunosuppression by Cyclosporine1 , 2005, The Journal of Immunology.

[9]  Liang Xie,et al.  Cyclophilin A Is a Proinflammatory Cytokine that Activates Endothelial Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Z. Galis,et al.  Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. , 2004, The American journal of pathology.

[11]  N. Perico,et al.  From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  D. Holt,et al.  Pharmacogenomics of immunosuppressive drug metabolism , 2003, Current opinion in nephrology and hypertension.

[13]  P. Fauchald,et al.  C2 monitoring in maintenance renal transplant recipients: is it worthwhile? , 2003, Transplantation.

[14]  J. Ha,et al.  Cyclosporine blocks muscle differentiation by inducing oxidative stress and by inhibiting the peptidylprolyl‐cistrans‐isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporine‐induced cytotoxicity , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  B. Kiberd,et al.  Adequate Early Cyclosporin Exposure is Critical to Prevent Renal Allograft Rejection: Patients Monitored by Absorption Profiling , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  M. Lassila.  Interaction of cyclosporine A and the renin-angiotensin system; new perspectives. , 2002, Current drug metabolism.

[17]  L. Truong,et al.  Cyclosporine A inhibits the adaptive responses to hypertonicity: a potential mechanism of nephrotoxicity. , 2001, Journal of the American Society of Nephrology.

[18]  C. Cardella,et al.  Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience. , 2001, Transplantation proceedings.

[19]  K. Budde,et al.  Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients. , 2001, Transplantation proceedings.

[20]  C. Yang,et al.  Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney. , 2001, Kidney international.

[21]  C. Yan,et al.  Cyclophilin A is a secreted growth factor induced by oxidative stress. , 2000, Circulation research.

[22]  W. Bennett,et al.  Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. , 2000, Kidney international.

[23]  S. Gygi,et al.  Purification and Identification of Secreted Oxidative Stress-induced Factors from Vascular Smooth Muscle Cells* , 2000, The Journal of Biological Chemistry.

[24]  V. Cairns,et al.  Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. , 1999, Transplantation.

[25]  G. Gamba,et al.  Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. , 1998, American journal of physiology. Renal physiology.

[26]  F. Pieruzzi,et al.  Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat. , 1996, Hypertension.

[27]  N. Perico,et al.  Two-hour post dose cyclosporine monitoring does not fit all in kidney transplantation , 2005 .

[28]  W. Bennett,et al.  Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. , 1997, Seminars in nephrology.

[29]  W. Bennett,et al.  Cyclosporine nephrotoxicity. , 2003, Seminars in nephrology.